Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/MD.0000000000003712 http://scihub22266oqcxt.onion/10.1097/MD.0000000000003712 C4998437!4998437 !27310951     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27310951 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Medicine+(Baltimore) 2016 ; 95 (24 ): e3712 Nephropedia Template TP {{tp|p=27310951 |t=2016. Recombinant thrombomodulin for secondary thrombotic thrombocytopenic purpura |pdf=|usr=}}{{27310951 }} gab.com Text Recombinant thrombomodulin for secondary thrombotic thrombocytopenic purpura JO: Medicine (Baltimore) http://www.kidney.de/pget.php?&tw=1&pmid=27310951 #FOAvip In the pathogenesis of thrombotic thrombocytopenic purpura (TTP), reductions in the enzyme activity of ADAMTS13, which cuts ultralarge von Willebrand multimers, generates shear stress on the microvascular endothelium, leading to platelet aggregation and the formation of a thrombus. ADAMTS13 activity is markedly decreased in typical TTP, but is only mildly reduced in secondary TTP, which concomitantly develops with primary disease. The latter develops with septic disseminated intravascular coagulation (DIC) and often causes organ failure. Recombinant thrombomodulin (rTM) is a drug that is used to treat DIC and may also remit TTP because it improves vascular endothelial dysfunction. Therefore, we herein investigated the efficacy of rTM in patients treated for the pathology of secondary TTP. Patients who were admitted to the Emergency and Critical Care Center of our hospital and met the following conditions were extracted and retrospectively analyzed: hemolytic anemia accompanied by fragmented red blood cells (Hb?<?12?g/dL or lower); thrombocytopenia (<100?×?10/?L); and ADAMTS13 activity <50%. Sixteen patients were included and accompanied by Kidney Disease: Improving Global Outcomes (KDIGO) stage 2 or more severe nephropathy and DIC. Eleven and 5 patients treated with and without rTM (the rTM and non-rTM treatment groups, respectively) were compared, and no significant difference was noted in their basic characteristics, such as background disease and severity. No significant difference was observed in survival rates; however, the platelet count, which is an important outcome of treatments for TTP, significantly increased in the rTM treatment group: 3.3?±?2.6?11.3?±?14.6 versus 3.5?±?3.7?5.7?±?3.9?(×1000/?L) (P = 0.034). Thrombotic thrombocytopenic purpura originally requires invasive treatments and its prognosis is not favorable. Blood thrombomodulin levels also markedly increase due to vascular endothelial dysfunction, whereas rTM alleviates vascular endothelial dysfunction in TTP patients with high blood TM levels, suggesting the importance of administering rTM. Thus, rTM may be effective for secondary TTP and may be adopted as adjuvant therapy. Twit Text FOAVip Recombinant thrombomodulin for secondary thrombotic thrombocytopenic purpura ????Medicine (Baltimore) http://www.kidney.de/pget.php?&tw=1&pmid=27310951 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27310951 #FOAvip English Wikipedia <ref>{{Cite pmid|27310951 }}</ref> Recombinant thrombomodulin for secondary thrombotic thrombocytopenic purpura #MMPMID27310951 Nakamura K ; Inokuchi R ; Hiruma T ; Ohshima K ; Sonoo T ; Tokunaga K ; Doi K ; Nakajima S Medicine (Baltimore) 2016[Jun]; 95 (24 ): e3712 PMID27310951 show ga In the pathogenesis of thrombotic thrombocytopenic purpura (TTP), reductions in the enzyme activity of ADAMTS13, which cuts ultralarge von Willebrand multimers, generates shear stress on the microvascular endothelium, leading to platelet aggregation and the formation of a thrombus. ADAMTS13 activity is markedly decreased in typical TTP, but is only mildly reduced in secondary TTP, which concomitantly develops with primary disease. The latter develops with septic disseminated intravascular coagulation (DIC) and often causes organ failure. Recombinant thrombomodulin (rTM) is a drug that is used to treat DIC and may also remit TTP because it improves vascular endothelial dysfunction. Therefore, we herein investigated the efficacy of rTM in patients treated for the pathology of secondary TTP. Patients who were admitted to the Emergency and Critical Care Center of our hospital and met the following conditions were extracted and retrospectively analyzed: hemolytic anemia accompanied by fragmented red blood cells (Hb? |ADAMTS13 Protein/*blood [MESH] |Aged [MESH] |Dose-Response Relationship, Drug [MESH] |Female [MESH] |Follow-Up Studies [MESH] |Humans [MESH] |Male [MESH] |Purpura, Thrombotic Thrombocytopenic/*drug therapy/enzymology [MESH] |Recombinant Proteins [MESH] |Retrospective Studies [MESH] |Thrombomodulin/*administration & dosage [MESH]Recombinant thrombomodulin for secondary thrombotic thrombocytopenic p(epmc).pdf DeepDyve Pubget Overpricing